Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma
Cancer Immunology, Immunotherapy, 08/02/2012
Phuphanich S et al. – Expression of four ICT–107 targeted antigens in the pre–vaccine tumors correlated with prolonged overall survival and PFS in newly diagnosed (ND)–glioblastoma (GBM) patients. The goal of targeting tumor antigens highly expressed on glioblastoma cancer stem cells is supported by the observation of decreased or absent CD133 expression in the recurrent areas of gadolinium–enhanced tumors.